Marker Therapeutics Q2 Loss Narrows 55%, But Going Concern Doubt Persists
MRKR sits 41% above its 52-week low of $0.81.
Summary
Marker Therapeutics narrowed its Q2 net loss to $1.8 million and extended cash runway into Q2 2027, but going concern doubt remains.
Key Events · Earnings and Guidance · MRKR
-
Going Concern Doubt
Management states substantial doubt about the company's ability to continue as a going concern, with cash runway only into Q2 2027.
-
Q2 Net Loss Narrows
Net loss was $1.8 million for Q2 2026, down 55% from $4.0 million in Q2 2025, driven by a 65% cut in R&D spending.
-
Cash Position Declines
Cash, equivalents, and restricted cash fell to $11.9 million from $17.0 million at year-end 2025.
-
New $4.2M Grant
In July 2026, the company received a $4.2 million grant from the U.S. Department of War for MT-601 in large B-cell lymphoma.
Analysis · MRKR · Life Sciences
Marker Therapeutics reported a Q2 2026 net loss of $1.8 million, down 55% from $4.0 million a year earlier, as R&D spending fell 65% to $1.5 million. Cash and equivalents dropped to $11.9 million from $17.0 million at year-end, funding operations into Q2 2027. The company again disclosed substantial doubt about its ability to continue as a going concern, a red flag that keeps this filing highly material despite the improved bottom line. A new $4.2 million Department of War grant and a 100-million-share increase in authorized common stock provide some runway, but the company still needs additional capital.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRKR was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.81 to $2.46. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.